# High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

> **NCT00735969** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 21 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peginterferon
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00735969
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735969, "High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00735969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*